News
NICE recommends migraine drug that could treat 10 000 patients in England
BMJ 2020; 368 doi: https://doi.org/10.1136/bmj.m1050 (Published 12 March 2020) Cite this as: BMJ 2020;368:m1050
- Elisabeth Mahase
- The BMJ
A drug to prevent chronic migraine could soon become available on the NHS for around 10 000 people in England, after the National Institute for Health and Care Excellence (NICE) found it to be cost effective.
In its draft guidance on the drug NICE has recommended fremanezumab (Ajovy, Teva Pharmaceuticals), citing clinical trial evidence presented by the manufacturer, which found that the drug reduced the number of monthly migraine days more than placebo for episodic and chronic migraine. …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.